Back to Product News Main Page

FDA Approves Angeliq^® to Treat Menopausal Symptoms

Berlex, Inc. announces that the U. S. Food and Drug Administration (FDA) has approved Angeliq^® (drospirenone and estradiol) to treat moderate to severe vasomotor symptoms associated with menopause. Angeliq will be the only hormone therapy to contain the unique progestin, drospirenone.

The estrogen component in Angeliq is estradiol, the same estrogen produced by the ovaries prior to menopause. The progestin drospirenone is a spironolactone analog with anti-aldosterone activity, a property that can cause the excretion of excess sodium and water while retaining potassium levels.

Angeliq will be available in the U.S. by prescription in mid-2006, in a preparation containing 0.5 mg drospirenone and 1 mg estradiol.

back to top